Unknown

Dataset Information

0

First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants.


ABSTRACT: SARS-CoV-2 and its variants have persisted in this ongoing COVID-19 pandemic. While the vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half of the world remain unvaccinated due to various reasons. Furthermore, the duration of the immunity gained from COVID-19 vaccination is still unclear. Therefore, there is a need for innovative prophylactic and treatment measures. In response to this need, we previously reported on the successful computer-aided development of potent VHH-based multispecific antibodies that were characterized in vitro. Here, we evaluated in vivo efficacy and safety of the lead trispecific VHH-Fc, ABS-VIR-001. Importantly, our data showed that ABS-VIR-001 treatment prevented SARS-CoV-2 infection and death when provided as an intranasal prophylaxis in a humanized ACE-2 mouse model. In addition, ABS-VIR-001 post-exposure treatment was shown to greatly reduce viral loads by as much as 50-fold. A detailed panel of metabolic and cellular parameters demonstrated that ABS-VIR-001 treatment was overall comparable to the PBS treatment, indicating a favorable safety profile. Notably, our inhibition studies show that ABS-VIR-001 continued to demonstrate unwavering efficacy against SARS-CoV-2 mutants, associated with key variants including Delta and Omicron, owing to its multiple epitope design. Lastly, we rigorously tested and confirmed the excellent thermostability of ABS-VIR-001 when heated to 45 °C for up to 4 weeks. Taken together, our study suggests that ABS-VIR-001 is an efficacious and durable prophylaxis and post-exposure treatment for COVID-19 with promising safety and manufacturability features for global distribution.

SUBMITTER: Titong A 

PROVIDER: S-EPMC8905027 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants.

Titong Allison A   Gallolu Kankanamalage Sachith S   Dong Jianbo J   Huang Betty B   Spadoni Nicholas N   Wang Bo B   Wright Meredith M   Pham Keegan L J KLJ   Le Anh Hai AH   Liu Yue Y  

Scientific reports 20220309 1


SARS-CoV-2 and its variants have persisted in this ongoing COVID-19 pandemic. While the vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half of the world remain unvaccinated due to various reasons. Furthermore, the duration of the immunity gained from COVID-19 vaccination is still unclear. Therefore, there is a need for innovative prophylactic and treatment measures. In response to this need, we previously reported on the successful computer-aided development  ...[more]

Similar Datasets

| S-EPMC7531565 | biostudies-literature
| S-EPMC8359631 | biostudies-literature
| S-EPMC8767641 | biostudies-literature
| S-EPMC10766394 | biostudies-literature
| S-EPMC1389705 | biostudies-literature
| S-EPMC9874498 | biostudies-literature
| S-EPMC3718736 | biostudies-literature
| S-EPMC5614562 | biostudies-literature
| S-EPMC4547275 | biostudies-literature